- Home
- IMMX vs SRZN Comparison
IMMX vs SRZN Comparison
Compare IMMX & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- SRZN
- Stock Information
- Founded
- IMMX 2014
- SRZN 2015
- Country
- IMMX United States
- SRZN United States
- Employees
- IMMX N/A
- SRZN N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- IMMX Health Care
- SRZN Health Care
- Exchange
- IMMX Nasdaq
- SRZN Nasdaq
- Market Cap
- IMMX 46.8M
- SRZN 38.1M
- IPO Year
- IMMX 2021
- SRZN N/A
- Fundamental
- Price
- IMMX $1.67
- SRZN $9.00
- Analyst Decision
- IMMX Strong Buy
- SRZN
- Analyst Count
- IMMX 1
- SRZN 0
- Target Price
- IMMX $7.00
- SRZN N/A
- AVG Volume (30 Days)
- IMMX 89.1K
- SRZN 33.9K
- Earning Date
- IMMX 11-12-2024
- SRZN 11-06-2024
- Dividend Yield
- IMMX N/A
- SRZN N/A
- EPS Growth
- IMMX N/A
- SRZN N/A
- EPS
- IMMX N/A
- SRZN N/A
- Revenue
- IMMX N/A
- SRZN $10,000,000.00
- Revenue This Year
- IMMX N/A
- SRZN N/A
- Revenue Next Year
- IMMX $200.00
- SRZN N/A
- P/E Ratio
- IMMX N/A
- SRZN N/A
- Revenue Growth
- IMMX N/A
- SRZN N/A
- 52 Week Low
- IMMX $1.26
- SRZN $6.00
- 52 Week High
- IMMX $7.75
- SRZN $16.19
- Technical
- Relative Strength Index (RSI)
- IMMX 50.69
- SRZN 45.92
- Support Level
- IMMX $1.65
- SRZN $8.10
- Resistance Level
- IMMX $1.93
- SRZN $10.76
- Average True Range (ATR)
- IMMX 0.16
- SRZN 1.25
- MACD
- IMMX 0.01
- SRZN -0.16
- Stochastic Oscillator
- IMMX 42.55
- SRZN 22.90
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).